TScan Therapeutics to Participate in the Morgan Stanley 19th Annual Global Healthcare Conference
WALTHAM, Mass., Sept. 02, 2021 – TScan Therapeutics (Nasdaq: TCRX) announced that its CEO, David Southwell, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 4:15 p.m. ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
WALTHAM, Mass., Sept. 02, 2021 – TScan Therapeutics (Nasdaq: TCRX) announced that its CEO, David Southwell, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 10, 2021, at 4:15 p.m. ET. A live webcast of the event will be accessible on the company’s website, with an archived replay available post-event.
TScan Therapeutics focuses on developing T-cell receptor engineered therapies for cancer treatment, including TSC-100 and TSC-101 for hematologic malignancies.
Details
News Market Reaction – TCRX
The recorded move for TCRX in the trading session of this news was +1.47%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
WALTHAM, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer, today announced that David Southwell, President and Chief Executive Officer, will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Friday, September 10, 2021 at 4:15 p.m. ET.
A live webcast of the fireside chat will be available on the “Events and Presentations” section of the Company’s website at ir.tscan.com. An archived replay of the webcast will be available on the Company’s website following the event.
About TScan Therapeutics, Inc.
TScan is a biopharmaceutical company focused on the development of T-cell receptor (TCR) engineered T cell therapies (TCR-T) for the treatment of patients with cancer. The company’s lead liquid tumor TCR-T therapy candidates, TSC-100 and TSC-101, are in development for the treatment of patients with hematologic malignancies to eliminate residual leukemia and prevent relapse after hematopoietic stem cell transplantation. The company is also developing multiplexed TCR-T therapy candidates for the treatment of various solid tumors.
Contacts
Media Contact:
David Rosen
Argot Partners
212-600-1902
david.rosen@argotpartners.com
Investor Contact:
Sherri Spear
Argot Partners
212-600-1902
sherri@argotpartners.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.